Genesys Spine Announces Positive Prospective Study Results for SIros® Lateral SI Joint Fusion System

The findings demonstrate significant pain reduction, functional improvement, and radiographic evidence of successful fusion.

Feb. 6, 2026 at 8:39am

Got story updates? Submit your updates here. ›

Genesys Spine announced the results of a prospective multicenter clinical study evaluating the safety and effectiveness of the SIros® Lateral Sacroiliac Joint Fusion System. The study showed a 38% reduction in pain scores, significant functional improvement, and radiographic evidence of successful fusion, reinforcing SIros as a leading minimally invasive option for patients with sacroiliac joint dysfunction.

Why it matters

The study confirms that the SIros system delivers pain relief and functional outcomes comparable to other titanium-based implants, while also achieving excellent safety, optimal operative parameters, and low fluoroscopic exposure, representing a major advancement for patient outcomes and recovery.

The details

The study showed a 38% reduction in pain scores by six months, with the mean Numerical Rating Scale (NRS) score decreasing from 6.8 at baseline to 4.2 (p<0.01). Functional outcomes also improved significantly, with the Oswestry Disability Index (ODI) improving from a baseline of 50.3% to 34.9% (p<0.01), representing a transition from severe to moderate disability. Radiographic assessments revealed that 96% of patients exhibited bone apposition to both iliac and sacral sides across at least two of the three implants, and 72% showed bridging across the SI joint at six months. Importantly, there were no reports of implant failure, device migration, or procedure-related serious adverse events. Additionally, opioid use among patients declined by nearly half over the course of the study.

  • The study was a prospective multicenter clinical study.

The players

Genesys Spine

A medical device company that announced the results of the study on the SIros® Lateral Sacroiliac Joint Fusion System.

Dr. Douglas P. Beall

The Principal Investigator of the study.

Meredith Gavlick

The Chief Strategy Officer of SI Fusion at Genesys Spine.

Got photos? Submit your photos here. ›

What they’re saying

“The study confirms that the SIros system delivers pain relief and functional outcomes comparable to other titanium-based implants, while also achieving excellent safety, optimal operative parameters, and low fluoroscopic exposure.”

— Dr. Douglas P. Beall, Principal Investigator (PRNewswire)

“The prospective study further validates SIros as a key solution for SI joint fusion. Demonstrating stabilization with minimal radiation exposure and a minimally invasive approach represents a major advancement for patient outcomes and recovery.”

— Meredith Gavlick, Chief Strategy Officer, SI Fusion (PRNewswire)

The takeaway

The positive results of this prospective study on the SIros® Lateral Sacroiliac Joint Fusion System reinforce it as a leading minimally invasive option for patients with sacroiliac joint dysfunction, delivering significant pain reduction, functional improvement, and radiographic evidence of successful fusion with excellent safety and low radiation exposure.